Veinviewer Flex: portable vascular access imaging device

30 03 2015

Veinviewer® Flex is a highly portable vascular access imaging device that can help you find the optimal venipuncture site and avoid potential complications.


With HD imaging and Df² technology, this small VeinViewer model is the brightest and only handheld vein illuminator that provides benefits for all patients during the entire Pre-, During- and Post- vascular access procedure. It is ideal for alternate care facilities, such as surgery and blood/plasma centers, as well as home healthcare and Emergency Medical Services (EMS), Veinviewer Flex is designed for durability and maximum portability. Flex is also suited for hospital departments such as the Emergency Department and NICU where space requirements and speed of assessment demand an ultra-portable and reliable vein finder.


How Does It Work?

With HD imaging and exclusive Df2 (digital full field) technology, Veinviewer is the only vein illuminator that provides benefits for all patients during the entire Pre, During and Post vascular access procedure.

Projected near-infrared light is absorbed by blood and reflected by surrounding tissue. The information is captured, processed and projected digitally in real time directly onto the surface of the skin. It provides a real time accurate image of the patient’ s blood pattern.

Veinviewer patented technology, using AVIN™ (Active Vascular Imaging Navigation), allows you to see blood patterns up to 15mm deep and clinically relevant veins up to 10mm. With VeinViewer clinicians can see peripheral veins, bifurcations and valves and assess in real time the refill/flushing of veins. With visualization Pre-, During- and Post-procedure, clinicians can potentially avoid complications from accidental puncture. Improving the total vascular access procedure, not just the stick.


 ASSESS Imaging Suite


Flex comes standard with our Universal imaging mode and is customizable to the full ASSESS™ Imaging Suite through optional upgrades:


Universal A benefit for all your patients.  The brightest and most accurate direct-projection, baseline mode available. Ideal for minimizing surface structures such as hair and wrinkles.
Fine detail * Enhances finer structures, ideal for identifying small veins in pediatric or sclerotherapy patients.
Inverse * Allows you to switch colors within the image window. This unique feature assists clinicians in customizing the projected image based on factors such as skin tone, density of hair follicles and room brightness.
Resize * Allows you to choose one of three window sizes, a valuable feature for pediatric patients or when you need to focus on only one vessel.
Image Capture * Allows the user to take and store up to 200 static images of patient vasculature on the device and transfer them to a PC for integration to HIS/RIS/PACS. No patient data is captured; HIPAA compliant. Excellent for documentation of vascular access site pre and post access, for setting expectations with aesthetics patients, and demonstrating outcomes.
Maxbright * Increases our market leading image brightness by another 40% for scenarios where greater than standard ambient lighting.

*Requires software upgrade. Call 877-SEE-VEIN for information on purchasing software.




Brightness Minimum of 5 lumens
Weight 1.6 lbs. (0.7 kg)
Dimensions 11.6″ x 4″ x 1.7″
Power source Fast-swap lithium ion batteries or AC (outlet)
Imaging/focal distance 12″ (30 cm), meets with AST recommendations for safe distance from the sterile field.

Veinviewer Flex uses no consumables, requires no patient contact and has no heat, laser eye-safety or radiation issues.

 Key specifications for alternate care providers like EMS:


  • Drop tested for quality and durability protecting your investment according to IEC/UL standard 60601-1.
  • Veinviewer Flex is rated as an EMC class B device and is suitable for use in all environments; both industrial and domestic.

For a list of EMS testing specifications call 877-SEE-VEIN



Veinviewer Flex comes standard with (2) S-Mounts and (2) Clamps so clinicians can mount the device to existing fixtures—allowing for hands-free, Eyes On Patient™ technique. Mount your VeinViewer Flex to tables, counter tops, bed rails and IV poles. There is no need to purchase (or clean) separate equipment.

Every Flex unit operates via AC power or battery so there is no fear of a “down” device. Each Flex comes standard with (2) fast-swap, rechargeable Lithium Ion batteries for up to 4 hours of continuous run time (approximately 2 hours per battery).

Here is a complete list of the VeinViewer Flex base accessory kit & standard items:


Included in every VeinViewer Flex base accessory kit:

(2) Fast-swap rechargeable Lithium Ion Batteries Up to 2 hours continuous run time per battery
Battery Charger Can be powered via AC Power or car charger
AC Power Adapter To be plugged into an outlet, or an ambulance cabin receptacle
International Power Adapters For use in: North America, EU, UK, China, Australia (Brazil adapter available upon request)
(2) S-Mounts (Stability Mount + C-Clamp and Super Clamp Systems) S-Mounts allow for hands-free, Eyes On Patient™ technique
(2) Clamps Clamps allow clinicians to affix S-Mount to: flat surfaces (tables, countertops), or round/square surfaces (bed rails, IV poles)
Storage case For convenient storage of Flex unit
Wrist strap For ease-of-use
Veinviewer Flex Connect PC Software To upgrade your device
USB Cable For connection to VeinViewer Connect PC software
Veinviewer In-Service Training Video Guide for using VeinViewer Flex

Optional accessories for VeinViewer Flex include a travel case (to hold the device, batteries and battery charger) and a car charger.

YouTube Preview Image [en línea] Memphis, TN (USA):, 30 de marzo de 2015 [REF. March of 2015] Available on Internet:

UNIVERSAL DOCTOR SPEAKER: communication between patients and healthcare professionals

26 03 2015

Functionality and sections



It is a mobile application which aims to facilitate multilingual communication between patients and health care anywhere in the world. On the one hand can go to citizens for, If you have to visit a doctor in a foreign country, they can can express themselves although it can also be very interesting that toilets can enjoy the application when they attend to people who speak other languages and is difficult to the realization of a basic history. In this sense, communication is bidirectional. No it's a simple general translator, but it caters specifically to the health world

The application is divided into sections that correspond to the following requirements:

  • Immediate medical needs.
  • Common general symptoms.
  • Symptoms for very urgent visits.
  • Accidents.
  • Events with violence.
  • Most common diseases.
  • Hospital admission.
  • Doubts about medical treatment.
  • Medical history and treatment as usual.

The available languages are: Spanish, Catalan, Arabic, Chinese, English, French, German, Japanese, Portuguese, Russian, Romanian, Chinese and the latest they have incorporated the Italian. So there is a very wide coverage of languages that we can communicate with.


Assessment and applicability

Although the ideal would be that the patient who is unknown in our language come accompanied by an interpreter, This situation rarely occurs and in the consultation we are presented with a problem of important communication that can cause major problems. I have used this application only on two occasions, but in both cases has been a great help having a very agile tool that has served to build bridges of communication between the patient and the health care. currently travellers and health care downloadable version IOS adapted to iPhone and iPad and Android adapted to Smartphone and Tablet version.

It not only offers us the translation of phrases or words most frequently used in health, but that allows us to play a locution of the own sentence. not allows to generate small records with basic information and treatments of patients who we may be attending.

On its website, we have access to other products and services such as the possibility of implementing the version professional WebApp in health centres with express translation services . This application with service included is normally acquired by hospitals, health centres and/or Governments of regions or countries with its introduction and customization of their respective intranets.

This WebApp can be customized according to the needs of the hospital/health centre. Some of the features of the professional version :

It offers more than 5000 medical phrases, explanations, questions and answers translated into more of 20 languages

  • Audio made by native speakers, It allows patients with disabilities to benefit from the service
  • The content has been carefully reviewed by medical professionals and professional linguists, In addition to being approved by different medical associations

Its website also present us new applications as Universal Nurse Speaker, a specific translator to the needs of nurses available in English, French, Spanish, Arabic, Russian and Romanian (1,99€) and UniversalWomen Speaker , a specific translator for the language needs during pregnancy and the birthing room (1,99 €). These ve€ons enjoy a reduced price to be in development phase. Coming soon new versions will be launched.



UniversalDoctor Speaker has recently received the international award as one of the best World Summit Award 40 applications around the world during the 2014. The award is an initiative of WISIS , UN agency

On his YouTube page they present interesting videos on this application

YouTube Preview Image

Technical data

Version: 1.6 updated the 14/08/2013

Universal Projects and Tools S.L..

Requires iOS 4.3 or later. Compatible with iPhone, iPad and iPod touch. This app is optimized for iPhone 5.

Languages: Spanish, German, Catalan, Chinese, French, English, Italian, Japanese, Polish, Portuguese, Romanian, Russian, Arabic

Price: 5,99€

José Francisco Tomás Ávila (@joseavil)Specialist in family and community medicine [en línea] Barcelona (ESP):, 26 March of 2015 [REF. December of 2014] Available on Internet: = 29

New antibody therapy dramatically improves psoriasis symptoms in clinical trial

23 03 2015

Many patients suffering from psoriasis showed significant recovery after just a single dose of an experimental treatment with a human antibody that blocks an immune signaling protein crucial to the disease, researchers report. By the end of the trial, conducted at Rockefeller University and seven other centers, nearly all of the 31 patients to receive treatment saw dramatic, if not complete, improvement in their symptoms

Skin deep: A sample from one psoriasis patient shows thickening of the outer layer of skin, known as the epidermis (top). Eight weeks after treatment, the epidermis has thinned to a normal level (bottom).


"The striking result we achieved using a human antibody that targets the signal interleukin-23 suggests we are on the threshold of doing something very different from our current model of treating psoriasis with immunosuppressive drugs throughout an adult lifetime,"says study author James Krueger, director of the Milstein Medical Research Program, (D). Martin Carter Professor in Clinical Investigation and head of the Laboratory of Investigative Dermatology. "It raises the possibility of working toward long-term remission — in other words, a cure. " The Journal of Allergy and Clinical Immunology published the results on Thursday (March 12).

Psoriasis is a debilitating disease in which the body's immune system mistakenly turns on the skin, producing red, itchy, scaly patches. In 2004, Krueger and colleagues suggested a dominant role for interleukin-23 in the disease, and research since then has supported this hypothesis. It appears that interleukin-23, a type of immune signaling molecule known as a cytokine, kicks off a cascade of interactions that leads to inflammation in the skin and excessive growth of skin cells and dilation of blood vessels.

The discovery of interleukin-23 's role has led to tests of a number of new antibody-based therapies that target it, but the compound, known as BI 655066, stands out. BYE 655066 is a human antibody that targets interleukin-23 and blocks it from binding to the receptors on cells that respond to it. Only a single treatment produced what the team describes as "rapid, substantial, and durable clinical improvement in patients with moderate-to-severe psoriasis. " On average, patients who received the treatment had a more than 80 percent improvement in the severity and extent of their skin lesions that continued until tracking ended six weeks after treatment. Meanwhile, genetic sequencing from skin samples revealed that the antibody's action reduced the expression of many of the cytokines and other molecules that define psoriasis.


J. Allergy Clin. Immunol. Online: March 12, 2015

Anti–il-23A mAb BYE 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

James G. Krueger, Laura K. Ferris, Alan Menter, Frank Wagner, Alexander White, Sudha Visvanathan, Bojan Lalovic, Stella Aslanyan, Elaine E.u.. Wang, David Hall, Alan Solinger, Steven Padula, and Paul School [en línea] New York, NY (USA):, 23 de marzo de 2015 [REF. 13 March of 2015] Available on Internet:

Chemical contaminant in fatty foods increases the risk of cancer in males

19 03 2015

An international study, which involved theUniversity of Granada, It shows that exposure to a chemical contaminant called PCB-153 is associated positively with the risk of cancer.

This compound, banned in Spain from the age of 80, It is present in many foods high in fats, like tuna or swordfish, due to its high resistance to degradation, the absence of even an effective elimination plan.

Part of the research group of the UGR, who has participated in this work. From left to right: Juan Pedro Arrebola, Marieta Fernández, Francisco Artacho, Inmaculada Jimenez and Rocio Perez Lobato.

An international study, which involved theUniversity of Granada, It has shown that exposure to a contaminant called chemical PCB-153 It is positively associated with the risk of cancer for males. This compound, banned in Spain from the age of 80, It is present in many foods high in fats, as fatty fish of big size (tuna, salmon and swordfish, among others), due to its high resistance to degradation.

In this work, published in the magazineScience of the Total Environment, participating institutions all including in the Biomedical Research Institute (IBS) Granada: the Universidad de Granada, the Complejo Hospitalario Universitario de Granada, the Andalusian School of public health, Cyber in epidemiology and public health (CIBERESP), and the Cancer Registry of Granada. In addition, a researcher belonging to the Bispebjerg University Hospital has participated in this work (Denmark).

As explained by the main author of this research, Juan Pedro Arrebola, of the Biomedical Research Institute (IBS), "today there is a growing trend in the incidence of various types of cancer, partly attributed to the influence of various environmental factors, as exposure to certain chemical contaminants".


A sample of 368 men and women

The objective of this study was to examine whether exposure to certain chemical contaminants, accumulated over time, It could be related to cancer risk. To do this, the scientists analyzed levels accumulated a group of contaminants in the fat of 368 adult men and women, residents in the province of Granada, and they collected the incidence of cancer throughout the nine years after recruitment.

"At the end of this time, We find that, among men, exposure accumulated to a pollutant PCB-153 call was positively associated with the risk of cancer. The PCB-153 belongs to a group of chemical compounds called polychlorinated biphenyls (PCBs), they were widely used in various industrial applications, including electrical transformers, industrial capacitors, hydraulic systems, sealants for buildings, pesticides, and even as plastic components", designates Arrebola.


PCBs in the environment and in people

While the use of PCBs was banned in Spain during the years 80, these compounds are still present both in the environment and in the majority of people, Thanks to its high resistance to degradation, as well as outdated equipment.

"It is estimated that fatty foods are the main route of exposure to PCBs in the general population, elevated levels of PCBs could be, in part, indicators of a fat-rich diet", highlights the researcher. On the other hand, It is suspected that PCBs can cause cancer through various mechanisms, including its interaction with hormone receptors of estrogens and androgens, the production of free radicals, or with DNA.

"As the cancer has a long latency period, our research group continues to follow this group of people to check if these preliminary findings are kept after a time of greater monitoring", concludes the UGR researcher.


Bibliographic reference:

Adipose tissue concentrations of persistent organic pollutants and total cancer risk in an adult cohort from Southern Spain: preliminary data from year 9 of the follow-up Arrebola JP, Fernandez MF, Martin-Olmedo P, Molina-Molina JM, Sanchez-Perez MJ, Sánchez-Cantalejo E, Molina-Portillo E, J exposito, Bonde JP, Olea N.SCI Total Environ. 2014 Dec 1;500-501:243-9. DOI: 10.1016/j.scitotenv.2014.08.043. EPUB 2014 Sep 15. PubMed PMID: 25217999 [en línea] Granada (ESP):, 19 March of 2015 [REF. 27 in January of 2015] Available on Internet:áncer-de-los-varones

Two apps to teach playing children with autism and Asperger's

16 03 2015

When we say that internet has radically changed our lives, Perhaps many do not realise until what point. Now, Thanks to mobile medicine or mHealth, apps can help many people with other abilities and sick in their day to day. And not only to them, but also to parents and caregivers.

Image | Erik Tjallinks

Autism and Asperger syndrome are two diseases that require delicate and special care. Developers have put hands to work to help parents and caregivers. An example of this is the imaginary Planet Foundation, Barcelona-based, dedicated to children with pervasive development disorder and who has opted for the world of apps to follow innovating methods. Has recently presented two of their 'Super Star products: an update of iSecuencias and AbaPlanet.

iSecuencias is based on 100 pre-programmed scenes that allow multiple combinations of exercises to learn basic structures of the language or perceive emotions. It is especially designed for children with Asperger syndrome or high functioning Autism. Victor Rodriguez, Clinical Director of Planeta Imaginario, now remember your birth, at the end of 2012.

YouTube Preview Image

"Presented by a contest of the Generalitat,, and we won it! The award allowed us to create iSecuencias 1.0 without any cost and be able to launch it to the market"says Rodriguez. Currently, has more of 80.000 downloads and have received several awards, "among them one of the" 50 best apps in Spanish related to health", granted by The App Date.

After the success of iSecuencias, they wanted more. And there came AbaPlanet, "more specialized and complete", allowing large and small work with the shapes of objects and the most basic vocabulary, classified in 18 categories: vehicles, clothing, food... The app is adapted to the child, 'deciding' content to work according to your pace of learning. It serves both to work in house and in therapy. This is how one of their exercises works: "The child must match an image of an object (for example a green shoe) with his equal or similar (with the Green shoe, or yellow shoe), in this way we work one very important prior to language, It is the recognition of objects and generalization", says Rodriguez.

YouTube Preview Image

With her, Imaginary planet wanted to "capture all our knowledge, the bases of the ABA (applied behavior analysis) and to create a tool that would work as close to how what we do in our sessions with children", explains Victor. His level of intelligence is such that knows when to help the child, What type of BRA offer and when to withdraw it to have ensured that it has learned well the word.

For the future they seek their apps to take one step further: "From now we want to continue to develop modules for the acquisition of more complex verbal skills as actions, colors, spatial adverbs"and others such as the empathy. the global landscape of applications for children with autism and Asperger syndrome is attractive, with numerous tools available, but Rodriguez explains that there is still much to do in Spain. In the same way, parents and educators are interested more and more by the ecosystem, "they know more and are more demanding with those apps that offer", highlights.

About eight years ago, This psychologist said you "that new technologies, and especially the world of tablets would be the future, and we had talked about that in the treatment of children with special needs could be a distinctive tool. At that time we believed that people were crazy... And look, now. They were visionaries!”


The competence center mHealth It is part of the international competition programme (EITHER) Mobile World Capital of Barcelona. mHealth works with a triple objective: identify opportunities for technology mobile in the provision of health services, transform processes and current health models and promote interoperability of health in the field of mobile technologies and connectivity services, building the foundations that allow you to integrate mobile health solutions.


Mobile World Capital Barcelona It is a foundation designed to transform the city into a center of reference of mobile technologies. A place where people, companies and institutions work together to harness the potential of mobile technologies as an element to transform everyday life and create new business opportunities. MWCB, through its programmes and initiatives, It is also an engine of development and internationalization of the business. [en línea] Barcelona (ESP):, 16 March of 2015 [REF. 24 de febrero de 2015] Available on Internet:

Earcones system to optimize the use of computing devices to visually impaired.

12 03 2015

Students and alumni of UPC create a system which helps blind people the use of computing devices.

 HUI system, which has won one of the awards ‘ Emprèn UPC’ for the best idea of technology-based business, It is based on digital synthesis of three-dimensional sound. The team that has created it works in the marketing of the system.

The prototype offers details of spaces through sound.

Holofonic User Interface (HUI) is a software solution that uses, in real time, the digital synthesis of three-dimensional sound so that users who are blind or visually impaired to use optimal computers, smartphones, video games, tablets and all kinds of computing devices with screen.

HUI is the result of project Oscar Martínez limit, of the School of engineering of Terrassa (TSE) the UPC, directed by Professor Antonio Calomarde, of the Department of electronic engineering the UPC.

The project is added since its inception Xavier Rodríguez, Bachelor's degree in computer engineering by the Barcelona School of Informatics (IBF) and, in the last few weeks, German Coínes, It developer. All three have developed a first prototype of this innovative system that allows the user to, no need to see, find the position of the icons that appear on the desktops of any computing device screens and perform its functions.

The team is now working on the commercialization of the system, He obtained the first prize in the competition Emprèn UPC to the best business idea.


Working with ‘ earcones’

 Holofonic User Interface System (User interface Holofonica, HUI) It is based on digital synthesis of three-dimensional sound. This technique allows you to integrate a characteristic sound digitally to an icon, making an earcone. The earcon designated folders, applications and programs from any device with Windows system. The user blind to open the computer installed some headphones home and begins to listen at the same time each one of the sounds that identify each earcone. To find what you're looking, just browse the desktop using the mouse.

The location of the exact position of the earcon is performed through the sounds that characterize them and also due to the differences in intensity of the sound when the mouse cursor approaches or moves away from them. When the user hears the sound that seeks the maximum intensity and not listen to any other, Click twice with the mouse and you can start using the program, the application or document you were looking for.

Find streets with GPS

 Another new feature of HUI is showing spatial information through sound. I.e., It allows not only to identify earcon, but also point the way to access sites, cities, or streets on a map of GPS without voice. The creators of HUI are viable to also apply the system in museums, Since it would indicate where a piece of art relative to the position of the visitor or even to include the content of the exhibition with three-dimensional sound.

Both students are already thinking to apply this same technology to touch devices, as smartphones or tablets, or even in gaming and augmented reality systems. According to the creators, This ingenious system will be a step further than the current systems of electronic voice card.

How designed

 In the development of HUI have been synthesized the three-dimensional sound. And shan used bases of data that model the outer ear human with real action on real subjects. Thanks to the existence of these databases, three-dimensional sound synthesis is very complex, but to do so in real time very fast processing and analysis capacity is needed. This is one of the secrets of the efficacy of HUI.

In addition, they have used a technique that has been already used in simulations of hearing or in virtual reality systems such as video games. For the first prototype have worked with Open Source computer languages, as Matlab and Pure Data, they have benefits in the field of sound processing in real time.

Oscar and Xavier presented their project Emprèn UPC technology based business ideas contest, convened by the programme it innovates at the same University and were the finalists. That is why INNOVA gave them the opportunity to train in the field of entrepreneurship in order to develop their business idea. At last, HUI turned out to be one of the winners, together with two other initiatives.

Business model and first applications

 In the first stage, HUI business model is based on the sale of licenses for the use of the application. Later, an application programming interface will be developed (API) that will allow to integrate the functionalities of HUI in your applications.

The creators of HUI intend to periodically distribute simple applications and mobile games, in order to publicize its possibilities. Is expected that the first is an augmented reality application that integrates 3D sound. [en línea] Barcelona (ESP):, 12 March of 2015 [REF. 04 in December of 2012] Available on Internet:http://saladepremsa/al-dia/mes-noticies/estudiantes-y-alumni-de-la-upc-crean-un-sistema-que-facilita-a-las-personas-invidentes-el-uso-de-dispositivos-informaticos

Triple therapy for Multiple Myeloma

9 03 2015

A global analysis shows benefits never before seen with triple pharmacological therapy for multiple myeloma.


In the treatment of the multiple myeloma, the addition of carfilzomib to currently accepted two-drug combination showed significantly better results than the application of only two drugs, He says a global research team led by scientists at Mayo Clinic.


The results were reported by internet the 6 December in the New England Journal of medicine (New England Journal of Medicine) and presented the 7 of December at the annual meeting of the American Society of Hematology (ASH, for its acronym in English) held in San Francisco.

Preliminary analysis of the clinical trial ASPIRE, who registered to 792 patients with relapse of myeloma multiple and from from 20 countries, He discovered an extension "never before" time view in which patients were free of all disease progression, says the study's principal investigator, Dr. Keith Stewart, oncologist of Mayo Clinic in Arizona. "Patients receiving all three drugs, of carfilzomib, lenalidomide and dexamethasone, did not show any progression of the disease for an average of 26 months", Adds doctor. "Never have I had reported anything in relapse of multiple myeloma".

Scientists discovered that carfilzomib to be added to the standard treatment (lenalidomide and dexamethasone) resulted in a referral 8,7 months long, What is it 50 percent higher than the one obtained with the normal combination of the two drugs (26,3 months to 17,6 months).

The number of patients who responded to treatment was also significantly increased with the addition of carfilzomib to normal therapy: 87,4 por ciento frente a 66,9 por ciento. In addition, After treatment with three drugs, the disease was undetectable at more than triple the patients (31,8 por ciento frente a 9percent versus Stewper cent out that, Despite the preliminary results, also there was a trend towards improved overall survival. "It is also important to note that patients receiving triple therapy reported better quality of life, Despite the increased intensity of the treatment", Adds.

These results highlight the growing success in the treatment of myeloma, the second most common type of blood cancer, says Dr. Stewart.

"The survival of multiple myeloma has nearly doubled in the last decade and as positive results of the implementation of the triple therapy possibly further improve it", refine your doctor. "It's a good topic to talk about".

Lenalidomide is a potent derivative of Thalidomide that affects the function of the immune system. Dexamethasone is a steroid. Carfilzomib is an inhibitor of the proteasome to in 2012 It received authorization from the administration of food and Drug Administration United States (FDA, for its acronym in English) for its application in patients with multiple myeloma advanced and terminal. The drug is specifically directed towards the regulation of proteins which nourish the growth of multiple myeloma.

The Studio ASPIRE discussed the implementation of the drug in patients less advanced. "There was concern that carfilzomib would increase side effects, especially when used with other two drugs", explains Dr. Stewart.

However, This was not a big problem, Adds doctor. "In reality, It seems that the frequency of the majority of the side effects, including severe toxicity, It was the same in both study groups. To ask patients how they felt, the response obtained practically from day one and throughout the study was reported feeling better with all three drugs. Carfilzomib yielded much better than people expected".

Mayo Clinic is one of the leaders in the clinical investigation of carfilzomib. Due to the experience of researchers at Mayo Clinic both basic and clinical research in the treatment of multiple myeloma, the promoters asked them to conduct phase I of the study on the substance. "We are first world centres in applying this drug and the first with a patient who already responded to it in the year 2006", says Dr. Stewart. The scientists from Mayo Clinic also participated in the studies phase II and received the request for the final clinical trial ASPIRE.

"We hope that the results of this trial will lead to the authorization of this combined therapy in patients with relapse of multiple myeloma in the world", says Dr. Stewart.

Onyx Pharmaceuticals, Inc., subsidiary of Amgen, financed the study.

El Dr. Stewart has offered consultancy to Onyx, but he has not personally received any compensation. El DDrewart has also provided consulting services in Celgene, Novartis, Bristol-Myers Squibb and Sanofi Aventis.


by Duska Anastasijevic



Information about the Cancer Center's may Clinic

As a main institution funded by the National Cancer Institute, the Cancer Center of Mayo Clinic conducts basic research, clinical and population to translate discoveries into better methods of prevention, detection, diagnosis, prognosis and treatment. If you want more information about clinical trials for cancer, call to the 507-538-7623.

Information about Mayo Clinic

In the year 2014 they are commemorated 150 years of service to humanity of this entity without profits and a world leader in medical care, research and education. If you would like more information, visit:, o [en línea] Phoenix, AZ (USA):, 09 March of 2015 [REF. 10 in December of 2014] Available on Internet:

Electronic alerts may do more harm than good for kidney patients

5 03 2015

The use of electronic alerts by hospitals treating patients with acute kidney injury may increase interventions without improving care, a study by Yale researchers found.

The study was published Feb. 25 in The Lancet.

Acute kidney injury (AKI) is a serious condition that can lead to dialysis and even death in hospitalized patients. To prevent these adverse outcomes, some hospital systems have proposed using electronic alerts to detect the condition at an early stage. To test the effectiveness of an alert system, first author Dr. (F). Perry Wilson, assistant professor of medicine at Yale, and his co-authors conducted a randomized trial with 2,400 patients at the Hospital at the University of Pennsylvania in Philadelphia.

The researchers randomized patients into one of two study groups: an AKI alert group and a "usual care" group with no alert. When a patient tested positive for AKI — determined by serum creatinine values — the provider and a pharmacist received an alert in the form of a text page informing them of the diagnosis and encouraging them to take appropriate steps. The message also included a link to a website with guidelines for managing AKI.

The researchers reviewed outcomes of the alert system at 7, 14, and 30 days after hospital admission. At the end of the eight-month study period, they were surprised by their findings.

"Our hypothesis was that it would improve outcomes,"said Wilson. "But we found that, overall, there was no effect. Informing the doctors did not change behavior, and it did not change outcomes in terms of dialysis or death. "

One reason may be because AKI is a condition with no clear-cut treatments, Wilson suggested. "I think we put this tool into the clinicians hands and didn't teach them how to use it."

While the alert system did not improve outcomes, in a subset of patients it did increase interventions, including more renal consultations and dialysis. These interventions, however, did not correlate with higher-quality care. "For acute kidney injury, more treatment is not necessarily better,"Wilson noted.

The study findings are notable because hospital systems, including the National Health Service in the United Kingdom, are moving toward increased use of electronic alerts. "We concluded that for AKI the alerts are ineffective,"Wilson said.

Other Yale authors Dr. Jeffrey Testani, Dr. Chirag R Parikh; additional authors are Dr. Michael Shashaty, Dr. Iram Aqeel, Yuliya Borovskiy, Susan Ellenberg, Dr. Harold I. Feldman, Dr. Hilda Fernandez, Dr. Yevgeniy Gitelman, Dr. Jennie Lin, Dr. Dan Negoianu, Dr. Peter P. Reese , Richard Urbani, and Dr. Barry Fuchs.

This work was funded in part by K23DK097201 and a Pen Center for Healthcare Improvement and Patient Safety Pilot Grant to FPW, K23hl114868 and L30HL115790 to JT, T32dk007006 to JL.

Citation: The Lancet

By Ziba Kashef [en línea] New Haven, CT (USA):, 05 March of 2015 [REF. 25 de febrero de 2015] Available on Internet:

Chronic Fatigue Syndrome Is a Biological Illness

2 03 2015

Scientists Discover Robust Evidence That Chronic Fatigue Syndrome Is a Biological Illness.

Immune Signatures in Blood Point to Distinct Disease Stages, Open Door to Better Diagnosis and Treatment


Mady Hornig, MD

Researchers at the Center for Infection and Immunity at Columbia University Mailman School of Public Health identified distinct immune changes in patients diagnosed with chronic fatigue syndrome, known medically as myalgic encephalomyelitis (ME/CFS) or systemic exertion intolerance disease. The findings could help improve diagnosis and identify treatment options for the disabling disorder, in which symptoms range from extreme fatigue and difficulty concentrating to headaches and muscle pain.

These immune signatures represent the first robust physical evidence that ME/CFS is a biological illness as opposed to a psychological disorder, and the first evidence that the disease has distinct stages. Results appear online in the new American Association for the Advancement of Science journal, Science Advances.

With funding to support studies of immune and infectious mechanisms of disease from the Chronic Fatigue Initiative of the Hutchins Family Foundation, the researchers used immunoassay testing methods to determine the levels of 51 immune biomarkers in blood plasma samples collected through two multicenter studies that represented a total of 298 ME/CFS patients and 348 healthy controls. They found specific patterns in patients who had the disease three years or less that were not present in controls or in patients who had the disease for more than three years. Short duration patients had increased amounts of many different types of immune molecules called cytokines. The association was unusually strong with a cytokine called interferon gamma that has been linked to the fatigue that follows many viral infections, including Epstein-Barr virus (the cause of infectious mononucleosis). Cytokine levels were not explained by symptom severity.

"We now have evidence confirming what millions of people with this disease already know, that ME/CFS isn’ t psychological,"states lead author Mady Hornig, MD, director of translational research at the Center for Infection and Immunity and associate professor of Epidemiology at Columbia's Mailman School. "Our results should accelerate the process of establishing the diagnosis after individuals first fall ill as well as discovery of new treatment strategies focusing on these early blood markers."

There are already human monoclonal antibodies on the market that can dampen levels of a cytokine called interleukin-17A that is among those the study shows were elevated in early-stage patients. Before any drugs can be tested in a clinical trial, Dr. Hornig and colleagues hope to replicate the current, cross-sectional results in a longitudinal study that follows patients for a year to see how cytokine levels, including interleukin-17A, differ within individual patients over time, depending on how long they have had the disease.


Stuck in High Gear

The study supports the idea that ME/CFS may reflect an infectious "hit-and-run" event. Patients often report getting sick, sometimes from something as common as infectious mononucleosis (Epstein-Barr virus), and never fully recover. The new research suggests that these infections throw a wrench in the immune system's ability to quiet itself after the acute infection, to return to a homeostatic balance; the immune response becomes like a car stuck in high gear. "It appears that ME/CFS patients are flush with cytokines until around the three-year mark, at which point the immune system shows evidence of exhaustion and cytokine levels drop,” says Dr. Hornig. "Early diagnosis may provide unique opportunities for treatment that likely differ from those that would be appropriate in later phases of the illness."

The investigators went to great lengths to carefully screen participants to make sure they had the disease. The researchers also recruited greater numbers of patients whose diagnosis was of relatively recent onset. Patients ' stress levels were standardized; before each blood draw, patients were asked to complete standardized paperwork, in part to engender fatigue. The scientists also controlled for factors known to affect the immune system, including the time of day, season and geographic location where the samples were taken, as well as age, sex and ethnicity/race.

In 2012, W. Ian Lipkin, MD, director of the Center for Infection and Immunity, and colleagues reported the results of a multicenter study that definitively ruled out two viruses thought to be implicated in ME/CFS: XMRV (xenotropic murine leukemia virus [MLV]-related virus) and murine retrovirus-like sequences (designated pMLV: polytropic MLV). In the coming weeks, Drs. Hornig and Lipkin expect to report the results of a second study of cerebrospinal fluid from ME/CFS patients. In separate ongoing studies, they are looking for "molecular footprints" of the specific agents behind the disease—be they viral, bacterial, or fungal—as well as the longitudinal look at how plasma cytokine patterns change within ME/CFS patients and controls across a one-year period, as noted above.

"This study delivers what has eluded us for so long: unequivocal evidence of immunological dysfunction in ME/CFS and diagnostic biomarkers for disease,” says Dr. Lipkin, senior author of the current study and the John Snow Professor of Epidemiology at Columbia's Mailman School. "The question we are trying to address in a parallel microbiome project is what triggers this dysfunction."

Co-authors include Andrew F. Schultz, Xiaoyu Che, and Meredith L. Eddy at the Center for Infection and Immunity; Jose G. Montoya at Stanford University; Anthony L. Komaroff at Harvard Medical School; Nancy G. Klaas at Nova Southeastern University; Susan Levine at Levine Clinic; Donna Felsenstein at Massachusetts General Hospital; Lucinda Bateman at Fatigue Consultation Clinic; and Daniel L. Peterson and Gunnar Gottschalk at Sierra Internal Medicine. The authors report no competing interests.

Support for the study was provided by the Chronic Fatigue Initiative of the Hutchins Family Foundation and the National Institutes of Health (Ai057158; Northeast Biodefense Center-Lipkin).



About Columbia University Mailman School of Public HealthFounded in 1922, Columbia University Mailman School of Public Health pursues an agenda of research, education, and service to address the critical and complex public health issues affecting New Yorkers, the nation and the world. The Mailman School is the third largest recipient of NIH grants among schools of public health. Its over 450 multi-disciplinary faculty members work in more than 100 countries around the world, addressing such issues as preventing infectious and chronic diseases, environmental health, maternal and child health, health policy, climate change & health, and public health preparedness. It is a leader in public health education with over 1,300 graduate students from more than 40 nations pursuing a variety of masters and doctoral degree programs. For more information, please visit [en línea] New York, NY (USA):, 02 March of 2015 [REF. 27 de febrero de 2015] Available on Internet: